



**AUXELLECE**

**Health Corporation**

## **Auxellence Announces Private Placement Financing at \$0.05 for Units of the Company with a Warrant at \$0.10**

VANCOUVER, BC, Monday, February 22, 2016 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF) “Auxellence” or the “Company” announces it is seeking financing to raise a \$1,500,000 to \$2,000,000 through a non-brokered equity private placement or alternatively debt financing, that shall be convertible for units of the Company (the "Units") at a price per Unit of CDN of \$0.05. Each Unit will consist of one common share and one common share purchase warrant of the Company, each such warrant entitling the holder to purchase an additional common share of the Company for a period of five years from the date of closing at a price of CDN of \$0.10 subject to any required hold or escrow provisions required by any regulators or the exchange. The funds are being applied towards working capital for the company.

The company invites all shareholders and any of the accredited investors, investment dealers, brokers, fund managers, exempt market dealers that it has met with or who may have an interest in participating in this financing to contact the company as soon as possible with any expression of interest.

### **Contact:**

Sydney Au, CEO

Auxellence Health Corporation

Email: [ceo@auxellence.com](mailto:ceo@auxellence.com)

Phone: (604) 780-3311

Website: <http://www.auxellence.com>

CSE Micro-site: <http://www.cnsx.ca/CNSX/Securities/Technology/Auxellence-Health-Corporation.aspx>

### **About Tulip™**

TULIP™ is a medical device cleared for sales in Canada and Europe as a blood pressure monitor with interactive protocols. The device enables physiologically interactive health apps useful in testing, tracking, and treating common health conditions. The online system is aimed primarily at “practicing patients” interested in normalizing blood pressure, blood glucose, and body weight. Session schedules, measurement procedures, and conditioning protocols are prescribed automatically by the system from extemporaneous data acquired from the user.



**AUXELLE**

**Health Corporation**

**About Auxellence Health Corporation (CSE: AID, OTCQB: AXHLF)**

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.

**Disclaimer for Forward-Looking Information**

Statements in this press release regarding the Company which are not historical facts are “forward-looking statements” that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbour.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES